R1 RCM — Q2 2018 Earnings Presentation
14 slides from R1 RCM's earnings presentation, Aug 9, 2018
Slide 1: Second Quarter 2018 Results Conference Call
Exhibit 99.2 Second Quarter 2018 Results Conference Call August 9, 2018
Slide 2: Forward-Looking Statements and Non-GAAP Financial Measures
Forward-Looking Statements and Non-GAAP Financial Measures This presentation includes information that may constitute “forward‐looking statements,” made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward‐looking statements relate to future, not pa
Slide 3: Q2 2018 Financial Highlights
Q2 2018 Financial Highlights . Revenue of $207.9 million, up $108.5 million year-over-year . GAAP net loss of $3.6 million compared to net loss of $6.7 million in Q2’17 . Adjusted EBITDA of $9.2 million, up $12.5 million year-over-year . On track to deliver 2018 revenue of $850-900 million, and adju
Slide 4: Customer Onboarding Update
Customer Onboarding Update . Intermountain Healthcare . 2,300 employees transitioned to R1 in early April . Rationalized 20% of targeted third‐party vendor spend . Centralized 65% of billing work relative to target . On track to launch state‐of‐the‐art technology and innovation center in Salt Lake C
Slide 5: Intermedix, Technology and Commercial Update
Intermedix, Technology and Commercial Update . Intermedix . Started to execute on integration plans post‐close; commercial functions fully integrated and integration of product portfolio is ahead of plan . Making investments to drive organic growth in Intermedix’s core business lines . Communicated
Slide 6: 2Q'18 non-GAAP Results – Q/Q and Y/Y Comparison
2Q’18 non-GAAP Results – Q/Q and Y/Y Comparison ($ in millions) 2Q’18 1Q’18 2Q’17 Key change driver(s) • Q/Q: Onboarding of Intermountain and contribution from Intermedix Revenue $207.9 $147.3 $99.4 • Y/Y: Onboarding of new customers and contribution from Intermedix • Q/Q and Y/Y: Onboarding of Inte
Slide 7: Additional Commentary
Additional Commentary . Net debt of $337.7 million as of 6/30/18, including restricted cash . Expect to start paying down debt with cash from operations in mid‐2019 . Net interest expense of $5.8 million in Q2’18 . Interest on subordinated debt paid in cash, did not exercise payment‐in‐kind option .
Slide 8: Financial Outlook
Financial Outlook1 ($ in millions) 2018 Outlook 2020 Outlook Revenue $850 – $900 $1,200 – $1,300 GAAP Operating Income ($30)‐($55) $115 – $155 Adjusted EBITDA $50 – $55 $225 – $250 NPR2 growth assumptions –$B Intermountain Health $4.6 Presence Health $2.2 AMITA Health $1.8 Ascension Medical Group $2
Slide 9: Appendix
Appendix
Slide 10: Use of Non-GAAP Financial Measures
Use of Non-GAAP Financial Measures . In order to provide a more comprehensive understanding of the information used by R1’s management team in financial and operational decision making, the Company supplements its GAAP consolidated financial statements with certain non‐GAAP financial performance mea
Slide 11: Reconciliation of Net Income (Loss) to Adjusted EBITDA
Reconciliation of Net Income (Loss) to Adjusted EBITDA Three Months 2018 vs. 2017 Six Months Ended 2018 vs. 2017 Ended June 30, Change June 30, Change 2018 2017 Amount % 2018 2017 Amount % (Unaudited) (Unaudited) Net income (loss) $ (2.9) $ (6.7) $ 3.8 (57 )% $ (26.2) $ (15.0) $ (11.2) 75 % Net inte
Slide 12: Reconciliation of GAAP to non-GAAP Financials
Reconciliation of GAAP to non-GAAP Financials Reconciliation of GAAP Cost of Services to Non‐GAAP Cost of Services $ in millions Three Months Ended Six Months Ended June 30, June 30, 2018 2017 2018 2017 Cost of services $ 189.9 $ 96.4 $ 328.6 $ 177.3 Less: Share‐based compensation expense 1.5 1.0 2.
Slide 13: Reconciliation GAAP Operating Income Guidance to non-GAAP Adjusted EBITDA Guidance
Reconciliation GAAP Operating Income Guidance to non-GAAP Adjusted EBITDA Guidance 2018 and 2020 Outlook $ in millions 2018 2020 GAAP Operating Income Guidance ($30)‐($50) $115‐$155 Plus: Depreciation and amortization expense $25‐$30 $30‐$40 Share‐based compensation expense $15‐$20 $20‐$25 Amortizat
Slide 14: Net Debt as of 6/30/18
Net Debt as of 6/30/18 $ in millions June 30, 2018 Current portion of long‐term debt $ 2.7 Long‐term debt 255.6 Long‐term debt ‐ related party 101.1 359.4 Unamortized discount and issuance costs (20.6) Total Debt (gross of discount and issuance costs) 380.0 Less: Cash and cash equivalents 38.8 Curre